Functional Improvement Seen in Dyne’s One-Year DM1 Trial Data
One-year data from six adults with myotonic dystrophy type 1 (DM1) treated with zeleciment basivarsen at 6.8 mg/kg every...
eClinical Tech News
Nurexone Shows Vision Recovery in Preclinical Glaucoma Model
Preclinical data from an optic nerve crush model showed that ExoPTEN, an exosome-delivered PTEN siRNA, produced a reproducible, dose-dependent...
New Parkinson’s Drug GT-02287 Shows Promising Phase 1b Data
Early interim data from Gain Therapeutics’ Phase 1b study of GT-02287 in Parkinson’s disease point to stability and improvements...
Neurona Expands NRTX-1001 Cell Therapy Trial for Epilepsy
In updated Phase 1/2 data for unilateral mesial temporal lobe epilepsy (MTLE), a single low dose of NRTX-1001 produced...
Atea’s New HCV Combo Aims for Best-in-Class Treatment
Atea reported 98% SVR12 (210/215) in the per‑protocol, treatment‑adherent cohort and 95% SVR12 (245/259) in the per‑protocol, regardless‑of‑adherence cohort...
Pembrolizumab & CNV-NT Combo Study Results in Solid Tumors
Biomed Valley Discoveries reported a 25% confirmed objective response rate (4 of 16 patients) with a median response duration...
Arvinas’ PROTAC Degrader Shows Positive Phase 1 Parkinson’s Data
ARV-102 delivered dose-dependent exposure in plasma and CSF, was well tolerated with no serious adverse events or discontinuations, and...
FDA Approves First PNS Device for Chronic Craniofacial Pain
Topline data: In a prospective, multi-center IDE randomized controlled trial for chronic craniofacial pain, 69% of patients on active...
Quantum MS Drug Breakthrough Moves Closer to Phase 2 Trial
Quantum BioPharma has received final 90-day oral toxicity and toxicokinetic reports for Lucid-21-302 (Lucid-MS), positioning the program to support...
Alterity Presents at 2025 Parkinson’s, Movement Disorders
In a randomized, double-blind Phase 2 study of 77 patients with multiple system atrophy (MSA), ATH434 delivered a clinically...